NSD2 and pancreatic adenocarcinoma: Moreover, the genetic alteration frequencies for NSD1, NSD2, and NSD3 in the PAAD cohort were 1.2%, 1.4%, and 2.1%, respectively (Figure 3C), with “amplification” as the primary alteration type and NSD3 identified as the most frequently altered gene.